LIG1 Loss Reveals Targetable Weakness Against Chemotherapy-Resistant Triple-Negative Breast Cancer
In triple-negative breast cancer (TNBC) that carries TP53 mutations, loss of one copy of the DNA ligase I gene (LIG1) ...
In triple-negative breast cancer (TNBC) that carries TP53 mutations, loss of one copy of the DNA ligase I gene (LIG1) ...
In a groundbreaking phase 2 clinical trial, researchers have demonstrated the efficacy of olaparib, a PARP inhibitor, in treating metastatic ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine